Topic

Toggle navigation

Genentech

In-network benefits

Unlike other big drugmakers facing do-or-die pressure to merge, Switzerland's Roche has found a third way: Invest in a web of research partners and diversify into diagnostic equipment.

August 07, 2005
This content is from: Research

Health Care: Biotechnology 2009

In a year when the biotechnology universe shrank — in March the first and biggest recombinant DNA company.
By Joshua Pasanisi
October 04, 2009
This content is from: Research

Health Care: Biotechnology 2008

Mark Schoenebaum, who joined Deutsche Bank Securities in June, after his former firm, Bear, Stearns & Co., was absorbed by JPMorgan Securities, remains “one of the most accessible, friendly and knowledgeable analysts in the sector,” according to one hedge fund manager.
By Joshua Pasanisi
October 09, 2008
This content is from: Portfolio

Will Something Turn Up?

Institutional investors need to take a long, hard look at venture capital.
By Udayan Gupta
August 13, 2010
This content is from: Premium

Viking Leads Tiger-Related Funds in Latest Biopharma IPO

Viking and Matrix Capital Management are the largest outside investors in Adaptive Biotechnologies.
By Stephen Taub
June 02, 2019
Sponsored

It's Ever Upward For Large-Cap Growth

"Back in 2003 or 2004, when the whole world was growing at 20% to 30%, we weren't so special," says Thomas Galvin, manager of the Excelsior Large-Cap Growth Fund. "Now, we're considerably special, because our companies tend to grow at two-to-three-times the clip of the rest of the market."

March 07, 2006
See More Articles